Steven L. Hoerter bought stock once, on Oct 17, 2025

Steven L. Hoerter (age 54) is a seasoned biopharmaceutical executive serving as Chairman of the Board at MBX Biosciences, Inc. (MBX), a clinical-stage company focused on peptide therapeutics for endocrine and metabolic diseases, since April 2025( He recently joined as a Director and has been involved in insider trading activities at MBX( Hoerter brings extensive commercial expertise, highlighted by his tenure as President & CEO of Deciphera Pharmaceuticals from March 2019 to October 2024, where he led the company through its acquisition by Ono Pharmaceutical, and prior roles as Chief Commercial Officer at Agios Pharmaceuticals (2016–2019) and Clovis Oncology (2015–2016), along with senior positions at Roche/Genentech, Chiron, and Eli Lilly(

Currently, Hoerter also serves as an independent Class II Director at C4 Therapeutics (CCCC) since November 2024, chairing the Organization, Leadership and Compensation Committee and joining the Audit Committee in 2025, and as a Director at ORIC Pharmaceuticals since August 2021( His educational background includes a B.A. from Bucknell University, an M.B.A. from Tilburg University, and an M.S. in management from Purdue University(

Written by Perplexity from public sources.